Soligenix Inc. buy Quitte
Start price
09.07.18
/
50%
€14.87
Target price
09.01.19
€33.79
Performance (%)
-8.18%
End price
09.01.19
€13.65
Summary
This prediction ended on 09.01.19 with a price of €13.65. With a performance of -8.18%, the BUY prediction by Quitte finished with a loss. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Soligenix Inc. | - | - | - | - |
| iShares Core DAX® | 0.476% | -0.039% | 13.342% | 17.330% |
| iShares Nasdaq 100 | 1.290% | 0.504% | 40.099% | 50.534% |
| iShares Nikkei 225® | 1.300% | -2.135% | 19.861% | 4.937% |
| iShares S&P 500 | 0.829% | 0.193% | 29.756% | 43.432% |
Comments by Quitte for this prediction
In the thread Soligenix Inc diskutieren
Quitte stimmt dem Sentiment von 'Buy' zu
= Soligenix ( SNGX ) early Monday said it has received notices of allowance from regulators for its patent applications in Europe and Canada extending protections for its proprietary ThermoVax vaccine heat stabilization platform technology. The main claims in these new patents cover formulations of the biotech company's RiVax thermostabilized ricin toxin vaccine.
(Laufzeit überschritten)